Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Stanford University
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
\>/= 18 years-old
Treated with Axicabtagene ciloleucel CAR-T therapy at Stanford Or
Treated with standard commercial Axicabtagene ciloleucel CAR-T therapy elsewhere and followed primarily by SHC Blood and Bone Marrow transplant providers
\>/= 6 months from the date of CAR-T infusion
Fluent in English
Able to attend and participate in in-person testing (Arm I)
Able to participate in remote video testing with adequate workspace, computer and internet capabilities for a reliable telehealth video connection (Arm II)
You may not be if
Concurrent enrollment in a CAR-T therapeutics research study
Unable to be present for the scheduled testing
Unable to participate in testing due to severe cognitive or physical limitation
Actively receiving chemotherapy
Progressive cancer
Clareo Health | Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford
